Crossject

Equities

ALCJ

FR0011716265

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:21 2024-04-26 am EDT			5-day change	1st Jan Change
2.02 ^EUR	+0.50%		-1.94%	-59.36%

Apr. 03	CROSSJECT : Patience is a virtue… hopefully	AL
Apr. 02	Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

CROSSJECT : Marketing initiative in the US

January 06, 2024 at 04:04 am EST

Marketing initiative in the US
LATEST

The group has engaged a supplier in the US to provide support for the pre-launch and launch activities.

FACT

Crossject has announced it has engaged Syneos Health, an integrated biopharmaceutical solutions organization, to prepare for the commercial launch of Crossject’s ZEPIZURE rescue therapy for epileptic seizures in the U.S.

ANALYSIS

Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE. Syneos Health brings a US presence and expertise in commercializing new therapies for Crossject.
Since the group is approaching a regulatory filing in the US, it is quite logical and useful to strengthen the group’s local marketing power, where it is also expanding Crossject’s presence. Note that the firm won an order placed by the BARDA (Biomedical Advanced Research and Development Authority) in the US and is in the process of filing to receive FDA authorization.
This news is reassuring as it confirms that group is active and confident about obtaining this authorization.

IMPACT

There is no impact on our numbers from this news as such, since it simply confirms that things are going in the right direction and moving forward.

Latest news about Crossject

CROSSJECT : Patience is a virtue… hopefully	Apr. 03	AL
Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
CROSSJECT : Invest Securities slightly reduces its target	Feb. 28	CF
CROSSJECT : Securing the financing needs	Feb. 28	AL
Crossject: share price falls after convertible bond issue	Feb. 27	CF
Crossject Société Anonyme announced that it expects to receive ?12 million in funding	Feb. 25	CI
CROSSJECT : No news is not always good news...	Feb. 08	AL
Crossject: strategy advances, but visibility worries	Feb. 07	CF
CROSSJECT : Marketing initiative in the US	Jan. 06	AL
Crossject: Syneos Health hired for Zepizure in the USA	Jan. 05	CF
French Pharmaceutical Crossject Taps Syneos Health for US Commercialization of Epilepsy Rescue Treatment	Jan. 05	MT
CROSSJECT : A new distribution agreement in Northern Europe	Jan. 03	AL
France's Crossject Inks New Commercialization Deal for Epileptic Seizure Therapy in Northern EU	Dec. 22	MT
Crossject: commercial agreement in Northern Europe	Dec. 22	CF
Crossject Signs ZENEO(R) Commercialization Agreement for Northern Europe	Dec. 22	CI
CROSSJECT : H1 23: no surprises before the release of the detailed accounts in October	23-09-28	AL
Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
Crossject: improved ESG rating in the Gaïa ranking	23-09-11	CF
Crossject: manufacturing audits passed	23-09-05	CF
Crossject Completes European, US Audits for Manufacturing of Seizure Medication for US	23-09-05	MT
AFT Pharmaceuticals Secures Australia, New Zealand License for Epilepsy Rescue Medication	23-07-20	MT
Crossject Société Anonyme Signs New Licensing Agreement on Zeno Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand	23-07-20	CI
Crossject: appointment to the Supervisory Board	23-06-02	CF
CROSSJECT : No real news in the FY22 results.	23-03-27	AL
CROSSJECT : FY22: not much to learn from the release	23-03-23	AL

Chart Crossject

Duration

Period

More charts

Company Profile

Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Sector

Medical Equipment, Supplies & Distribution

More about the company